Dr. Jimmy Lin

Cancer Genomics Pioneer


Dr. Jimmy Lin, MD, PhD, MHS has devoted his life to beating cancer.

  • At Johns Hopkins, he helped perform the first genome-wide sequencing of human cancers - including colorectal, breast, pancreatic, melanoma, and brain cancers.
  • At the Washington University in St. Louis, he was part of one of the first academic clinical next-generation sequencing efforts.
  • At the National Cancer Institute (NCI) at the National Institutes of Health (NIH), he built and led the intramural clinical genomics (ClinOmics) program.
  • Currently, he is the Chief Scientific Officer (CSO), Oncology at Natera (NASDAQ: NTRA), developing blood-based DNA assays to detect cancer early and monitor is during treatment.

In addition, he has leveraged the technological advances in cancer to fight rare diseases as the Founder and President of the Rare Genomics Institute.



Dr. Lin has published over 100+ papers, book chapters, and abstracts including top academic journals such as Science, Nature, and Cell and has spoken at top universities such as Harvard, Yale, and Stanford.



Dr. Lin has delivered over 100+ keynotes, speeches, and panels in 19 countries on 5 continents, including TED, Aspen Ideas Festival, Google, the White House and the European Commission.


Thought Leader

Dr. Lin has been featured or mentioned in over 300+ media outlets including New York Times, Washington Post, CNN, Financial Times, Forbes, BBC, WIRED and TIME.